Timing is Everything; Tempo Raises Series A

Polaris Venture Partners has done quite well with what might broadly be called pharmaceutical technologies—businesses based on drug delivery and reformulation, rather than discovery. Their secret weapon: the Massachusetts Institute of Technology and, in particular, researcher Robert Langer, ScD.

Now they’re turning the crank again, though this time Langer is merely a key MIT connection (and a board member).